WithdrawnPhase 4

A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED

Stopped: The ED physicians no longer prescribe opioids at discharge; not feasible to conduct the study

United States0Started 2019-09-01

Plain-language summary

This is a prospective randomized, clinical trial comparing recurrent use of Morphine Sulfate Immediate Release (MSIR), Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at discharge from the emergency department for opioid-naive adult patients presenting with moderate-to-severe pain. At discharge, patients will be randomized to receive either 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days, 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days, or 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days. At 1 month, 3 months, and 6 months patients' prescription's history will be accessed by using the DoctorFirst Drug Database to determine the recurrent use that will serve as a surrogate marker of likeability and abuse liability of each prescribed opioid.

Who can participate

Age range18 Years – 120 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ED patient * 18 and older * acute to moderate to severe pain * requires oral opioid medications at ED discharge. Exclusion Criteria: * chronic non-cancer and cancer pain, * patients with history of substance abuse * patients with opioid use disorder, * patients simultaneously taking antidepressants, benzodiazepines and other sedative-hypnotics, * and allergies to any of the medications.

What they're measuring

Percentage of Patients using Prescribed Medication at 1 month

Timeframe: 1 month

Trial details

NCT IDNCT03529331

SponsorAntonios Likourezos

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-31